PE-22-28 vs Semax
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PE-22-28
PE-22-28 is a synthetic peptide fragment derived from research on the SAMP8 mouse model of accelerated aging. It has shown potential for enhancing memory and reducing cognitive decline.
Full details →Semax
Semax is a synthetic peptide derived from ACTH (adrenocorticotropic hormone). Developed in Russia as a nootropic and neuroprotective agent.
Full details →Side-by-Side Comparison
| Aspect | PE-22-28 | Semax |
|---|---|---|
| Mechanism | Derived from the protein that is deficient in SAMP8 mice. May work by inhibiting protein phosphatase 2A methylesterase, thereby affecting memory-related signaling pathways. | Enhances BDNF expression, modulates dopamine and serotonin systems, and provides neuroprotective effects. Increases attention, memory formation, and learning. |
| Typical Dosage | Research protocols vary. Intranasal dosing has been studied at various concentrations. Optimal human dosing not established. | Intranasal: 200-600mcg 2-3 times daily. Higher doses (up to 1mg) used in clinical settings for stroke recovery. |
| Administration | Intranasal administration preferred for CNS delivery. Research compound with limited human use data. | Primarily administered intranasally. N-Acetyl Semax Amidate (NASA) is a modified version with enhanced stability and potency. |
| Side Effects | Very limited human data. Primarily studied in animal models for safety and efficacy. | Generally well-tolerated. May cause mild irritability or hair shedding in some users. |
| Best For |
What They Have in Common
Both PE-22-28 and Semax are commonly used for: